ALPS Group Inc Ordinary Share (ALPS) is a publicly traded the market company. As of May 21, 2026, ALPS trades at $0.71 with a market cap of $141.46M and a P/E ratio of 1.08. ALPS moved +0.00% today. Year to date, ALPS is -31.42%; over the trailing twelve months it is flat. Its 52-week range spans $0.56 to $2.90. Rallies surfaces ALPS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alps Group Reports Nine-Patient NK Cell Safety Study Using Patent-Pending Protocol: Alps Group reported a peer-reviewed case series of nine patients receiving autologous NK cell infusions cultured via its proprietary, antibody-free protocol, demonstrating tolerability with no dose-dependent toxicities and cytotoxic activity against cancer cell models. The patent-pending in-house culture method (PI2025002484) enables cost-effective, large-scale NK cell production for future clinical trials.
| Metric | Value |
|---|---|
| Price | $0.71 |
| Market Cap | $141.46M |
| P/E Ratio | 1.08 |
| EPS | $0.71 |
| Dividend Yield | 0.03% |
| 52-Week High | $2.90 |
| 52-Week Low | $0.56 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $221.78M |
| Net Income | $62.85M |
| Gross Margin | 0.00% |
ALPS analyst coverage data. Average price target: $0.00.